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Background: The natural course of sexually transmitted infections caused by 21 
Chlamydia trachomatis varies between individuals. In addition to parasite and 22 
host effects, the vaginal microbiota might play a key role in the outcome of C. 23 
trachomatis infections. Interferon-gamma (IFN-γ), known for its anti-chlamydial 24 
properties, activates the expression of indoleamine 2,3-dioxygenase (IDO1) in 25 
epithelial cells, an enzyme that catabolizes the amino acid L- tryptophan into N-26 
formylkynurenine, depleting the host cell’s pool of tryptophan. Although C. 27 
trachomatis is a tryptophan auxotroph, urogenital strains (but not ocular strains) 28 
have been shown in vitro to have the ability to produce tryptophan from indole 29 
using the tryptophan synthase (trpBA) gene. It has been suggested that indole 30 
producing bacteria from the vaginal microbiota could influence the outcome of 31 
Chlamydia infection.                                                                                                                      32 
Results: We used two in vitro models (treatment with IFN-γ or direct limitation 33 
of tryptophan), to study the effects of direct rescue by the addition of exogenous 34 
indole, or by the addition of culture supernatant from indole-positive versus 35 
indole-negative Prevotella strains, on the growth and infectivity of C. 36 
trachomatis. We found that only supernatants from the indole-positive strains, 37 
P. intermedia and P. nigrescens, were able to rescue tryptophan-starved C. 38 
trachomatis. In addition, we analyzed vaginal secretion samples to determine 39 
physiological indole concentrations. In spite of the complexity of vaginal 40 
secretions, we demonstrated that for some vaginal specimens with higher 41 
indole levels, there was a link to higher recovery of the Chlamydia under 42 
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tryptophan starved conditions, lending preliminary support to the critical role of 43 
the IFN-γ-tryptophan-indole axis in vivo. 44 
Conclusions: Our data provide evidence for the ability of both exogenous 45 
indole as well as supernatant from indole producing bacteria such as Prevotella, 46 
to rescue genital C. trachomatis from tryptophan starvation. This adds weight 47 
to the hypothesis that the vaginal microbiota (particularly from women with 48 
lower levels of lactobacilli and higher levels of indole producing anaerobes) may 49 
be intrinsically linked to the outcome of chlamydial infections in some women. 50 
Keywords: Tryptophan-synthase, interferon-γ, microbiota. 51 
 52 
Background 53 
Chlamydia trachomatis is an obligate intracellular bacterium with a unique 54 
biphasic developmental cycle. The cycle begins with the uptake of the infectious 55 
elementary body form (EB) by the host cell. The EB remains in a membrane-56 
bound vacuole termed an inclusion, where it differentiates into the non-57 
infectious, reticulate body form (RB). The RBs undergo cell division. After 8-12 58 
rounds of multiplication, and inclusion growth, RBs asynchronously convert 59 
back to the EB form [1,2]. At 30-68 hours post infection (PI), depending on the 60 
infecting strain, the EBs are released from the host cell [3]. However, under 61 
stressful growth conditions such as nutrient starvation, exposure to antibiotics 62 
or immune factors such as interferon-gamma (IFN-γ) [4–6], the chlamydial cycle 63 
is disturbed and the RBs convert to enlarged, non-infectious, aberrant bodies 64 
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(ABs) [1,3,7,8]. Once the stress factor is removed, the Chlamydia revert to the 65 
active developmental cycle [3,8,9].  66 
Genital C. trachomatis infections remain a major health problem.  Worldwide, 67 
an estimated 131 million sexually transmitted C. trachomatis infections occur 68 
each year [10]. In women, the severity of the infection as well as the probability 69 
to progress to complications varies among individuals. Complications such as 70 
pelvic inflammatory disease (PID) and infertility are common following C. 71 
trachomatis infection [11–13] and may be associated with the participant's 72 
inability to fully clear their infection, or a history of repeat infections [13–16]. The 73 
proinflammatory cytokine interferon-γ (IFN-γ) is known for its central role in 74 
inflammation and autoimmunity [17]. This cytokine is upregulated upon 75 
infection [18,19] and has inhibitory effects on C. trachomatis [19,20]. IFN-γ has 76 
many effects but for Chlamydia most significant appears to be the induction of 77 
expression of the enzyme indoleamine 2,3-dioxygenase (IDO), in epithelial 78 
cells, that catalyses the degradation of the essential amino acid, L-tryptophan 79 
into N-formylkynurenine [21]. Depletion of the host cell tryptophan pools causes 80 
the Chlamydia, a tryptophan auxotroph, to enter its persistent form [22], evident 81 
in vitro by enlarged, aberrant bodies (ABs) (or die at severe depletion) [5,23].  82 
When the tryptophan is restored, in vitro evidence shows that the Chlamydia 83 
returns back to its infectious state [24,25]. While different chlamydial strains 84 
have a range of sensitivity levels to IFN-γ treatment in vitro [9,26], high 85 
concentrations are lethal. C. trachomatis genital (D-L), but not ocular (A-C) 86 
strains, have a functional tryptophan synthase gene (trpBA) [25–28], which 87 
enables them to synthesise tryptophan from indole. Addition of exogenous 88 
indole to the cell culture, can rescue the genital C. trachomatis strains from IFN-89 
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γ exposure, enabling them to subsequently produce infectious progeny 90 
[27,29,30].  91 
In addition to the host immune response [16], C. trachomatis infection risk is 92 
increased during episodes of bacterial vaginosis (BV), which is characterized 93 
by reduced levels of lactobacilli and a higher proportion of anaerobic bacteria 94 
in the vaginal tract [31–34]. One hypothesis described by Morrison et al. [35], 95 
suggested that indole producing bacteria in the vaginal flora might contribute to 96 
the survival of the Chlamydia by providing a source of indole at the infection 97 
site [24,27,35–37]. In this study, we directly investigated the effect of indole 98 
producing bacteria, such as Prevotella, on C. trachomatis recovery after 99 
tryptophan starvation. Our results show that supernatant from indole producing 100 
Prevotella intermedia and Prevotella nigrescens, but not indole negative 101 
Prevotella bivia, can rescue C. trachomatis after tryptophan starvation in vitro. 102 
In addition, vaginal secretions from five women had different effects on the 103 
recovery of the Chlamydia after tryptophan starvation.   104 
Methods 105 
C. trachomatis in vitro culture conditions 106 
The C. trachomatis isolates used in this study included: C. trachomatis serotype 107 
D (ATCC VR-885), C. trachomatis serotype C (ATCC VR-1477). Isolates were 108 
routinely cultured in HEp-2 cell line (ATCC CCL-23) with DMEM (Gibco, 109 
Australia) containing 5% heat inactivated fetal calf serum (FCS) (Life 110 
Technologies, Australia), 120 µg/ml streptomycin (Sigma-Aldrich, Australia), 50 111 
µg/ml Gentamycin (Gibco, Australia), 37°C, 5% CO2. All experiments were 112 
conducted in 48-well plates at a multiplicity of infection (MOI) of 0.5. For the 113 
6 
 
IFN-γ-induced tryptophan starvations experiments; 25,000 cells/well were 114 
seeded 48 h before infection, in the presence of different concentrations of 115 
human IFN-γ (Peprotech, Australia). IFN-γ treatment was replenished every 24 116 
h until the rescue time point. For the tryptophan free media experiments (Jomar 117 
Life Research, Australia), 50,000 cells/well were seeded 24 h before infection. 118 
At the time of infection, the HEp-2 monolayer was at around 90% confluence. 119 
Fresh media and appropriate treatments were supplied to the culture every 24 120 
h and the infectious yields were measured at 36/60/72 h PI (depends on the 121 
specific experiment- see figures legend). Infected cells and culture 122 
supernatants were then sonicated and used to infect a new HEp-2 cell 123 
monolayer in three replicates, for enumeration of recoverable inclusion forming 124 
units (IFUs). After staining with anti-HtrA and goat anti rabbit IgG (H+L) Alexa 125 
Flour 488 (Invitrogen, Australia), wells were visualized for inclusion presence 126 
using fluorescence microscopy (Nikon Eclipse TiS Fluorescent Microscope) 127 
[38,39]. The IFU/ml were determined for each condition by measuring the 128 
number of inclusions in multiple wells, taking into account the dilution and 129 
volume from the original culture. The limit of detection of the assay is 102 130 
IFU/ml. Rescue experiments using an IFN-γ-induced tryptophan starvation 131 
model were conducted following three washes with phosphate-buffered saline 132 
(PBS). Rescue experiments using tryptophan-depleted media were conducted 133 
with the addition of tryptophan, indole, bacterial isolates supernatant or cervical 134 
secretions, in the presence of cycloheximide, at 36 h PI and were incubated for 135 
further 36 h. Control cultures with normal tryptophan supply, as well as 136 
tryptophan depleted conditions without rescue, were included in all 137 
experiments. In all 'No rescue' treatments, cultures were harvested to check 138 
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chlamydial recovery at 36 h PI. Morphological observation of the chlamydial 139 
inclusions in tryptophan-free media was made in several of the treatments using 140 
Chlamydia LPS stain (Cellabs, Australia) and visualised using confocal 141 
microscopy (Nikon Eclipse Ti) (Supplementary Figure 1). For the morphological 142 
observations, cultures were fixed with methanol at 36 h PI (Supplementary 143 
Figure 1A), and at 72 h PI (Supplementary Figure 1B, C). 144 
In vitro rescue of C. trachomatis with supernatant from indole 145 
positive/negative bacteria 146 
Indole producing bacteria, P. intermedia (ATCC 25611) and P. nigrescens 147 
(ATCC 33563), and a non-indole producing bacterium P. bivia (vaginal isolate), 148 
were cultured in BHI broth 37°C/36 h in anaerobic conditions. OD600 was 149 
measured and corrected for all strains to OD=1. Indole production was 150 
confirmed using Kovac's reagent (Sigma-Aldrich, Australia). Bacterial broth was 151 
centrifuged 3000×g/10min/RT and supernatant was collected and filter 152 
sterilised with 0.22 µM filter. Supernatant was added to the tryptophan deprived 153 
C. trachomatis infected cell culture at 36 h PI. Infected cells and culture 154 
supernatants were sonicated at 72 h PI and were used to infect a new HEp-2 155 
cell monolayer for enumeration of recoverable IFUs.  156 
RNA extraction and reverse transcription 157 
C. trachomatis infected cell culture samples were stored in RNAlater. Total RNA 158 
was extracted from the cells using RNeasy mini kit (Qiagen, Australia), 159 
according to the manufacturer's instructions. The RNA concentration and purity 160 
was determined using Nano-drop Spectrophotometer. 0.2 µg of total RNA was 161 
reverse transcribed using QuantiTect Reverse transcription kit (Qiagen, 162 
Australia), in accordance with the manufacturer’s instructions. 163 
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C. trachomatis trpBA transcript expression 164 
The primers sequences were taken from Carlson et al., paper [30], with minor 165 
changes to complement C. trachomatis serotype D. Forward primer for trpBA 166 
amplification: 5'-GCATTGGAGTCTTCACATGC-3’, and reverse primer: ‘3-167 
ACACCTCCTTGAATCAGAGC-5’. Amplification was carried out according to 168 
the manufacturer's instructions using QuntiNova SYBR Green PCR kit (Qiagen, 169 
Australia). The cycling program was 95°C for 2 min followed by 40 cycles of 5 170 
sec at 95°C and 10 sec at 60°C. Transcript levels were quantified using Rotor-171 
GeneQ (Qiagen, Australia). Results were normalized against the mRNA of C. 172 
trachomatis-specific ompA gene transcripts (using previously described 173 
primers [40]) in each cDNA preparation. Results are presented as normalised 174 
values of 2-ΔΔCT. 175 
 176 
Elution of vaginal secretions and Indole concentration measurement 177 
LASIK PVA eye sponges (Visitec) were placed in the posterior fornix of the 178 
vagina for two min to absorb secretions [41]. Sponges were immediately placed 179 
in -20°C until vaginal fluid was extracted the same day. Vaginal fluid was eluted 180 
from sponges using 300 µl of PBS. Total indoles were quantified using 181 
Salkowski’s test [42], modified as described by Szkop et al. [43]. Briefly, serial 182 
dilutions of indole (Sigma-Aldrich, Australia) were used in order to generate a 183 
standard curve by measuring absorbance at 530 nm, following incubation with 184 
Salkowski's reagent. Indole concentrations were corrected for the dilution factor 185 
of the samples. 186 
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Participant details and sample collection procedures  187 
Samples were collected from a small study in reproductive-age women who 188 
were either, negative for, or infected with C. trachomatis, attending the sexual 189 
health clinic in Nambour, Australia. All participants provided informed written 190 
consent to participate in the study. Two Chlamydia negative and three 191 
Chlamydia positive women were recruited to the study. Chlamydia testing 192 
(positive/negative) was performed by the Nambour STI Clinic. High vaginal 193 
swab sample and cervical secretion sample were collected from each 194 
participant to enumerate chlamydial infection load and indole concentration. 195 
Participants' secretion samples were evaluated for their indole content as 196 
described above. Secretions were added to the tryptophan starved culture at 197 
36 h PI to evaluate the Chlamydia recovery effect. The secretions were added 198 
in different dilutions (1:100, 1:1,000, 1:10,000), as well as secretions at 199 
1:10,000 dilution with the addition of 0.5 µM indole. 200 
Statistical analyses 201 
All cell culture experiments (Figures 1-6) were conducted in triplicate. The 202 
IFU/ml was determined for each condition by measuring the number of 203 
inclusions in multiple wells, and accounting for the dilution and volume from the 204 
original culture. Data were analysed using Prism GraphPad V.6 and presented 205 
as the mean ± SD IFUs (n=9) determinations. Statistical significance in figure 6 206 
was determined using two-way ANOVA and p- values were calculated using 207 
Tukey's multiple comparison test. For figure 4 statistical significance was 208 
determined via multiple t testing using the Holm-Sidak method, with alpha = 0.05, 209 




IFN-γ- induced tryptophan starvation and rescue 212 
We first established an in vitro assay using IFN-γ treated HEp-2 cells, infected 213 
with either C. trachomatis genital (serovar D) or ocular (serovar C) strains, and 214 
demonstrated different abilities of these strains to recover following the addition 215 
of tryptophan (fresh 'DMEM') or indole (10 µM) (Figure 1), after IFN-γ treatment. 216 
HEp-2 cells were infected with C. trachomatis and incubated in the presence of 217 
different IFN-γ concentrations (0, 150, 500 U/ml) for 36 h. At the time of 218 
recovery; 36 h PI, without rescue ('No rescue' treatment), no inclusions were 219 
detected. Consistent with the literature, our data showed that both strains were 220 
able to recover from IFN-γ treatment (36 h) when the IFN-γ was removed and 221 
replaced with fresh DMEM containing 78.3µM (16 mg/L) L-tryptophan (as per 222 
the manufacturer’s description). For C. trachomatis D, treatment with 500 units 223 
of IFN-γ resulted in no remaining infectious organisms but when fresh DMEM 224 
was added, 4.9 x 103 IFUs/ml were recovered. The ocular strain, C, also 225 
showed 1.2 x 102 IFU/ml recovery under similar conditions. When exogenous 226 
indole (rather than DMEM containing exogenous tryptophan) was used for the 227 
recovery step, the genital strain D showed a very high (2.1 x 105) recovery of 228 
IFUs/ml, as there was no competition from the host cell for indole, whereas the 229 
ocular strain C did not show any additional recovery (compared to DMEM 230 
alone). Next, we investigated a range of exogenous indole concentrations on 231 
recovery and found that levels of 0.25 µM and higher resulted in high levels of 232 
recovery, even when the cultures were originally treated with 1000 units/ml of 233 
IFN-γ (Figure 2).  234 
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Figure 1 goes here 235 
Figure 2 goes here 236 
C. trachomatis D recovery using tryptophan or indole in a tryptophan-237 
depleted media model 238 
The model of C. trachomatis inhibition using IFN-γ, cultured with DMEM, is 239 
problematic, as the media contains large amounts of tryptophan. Therefore, we 240 
used a model using tryptophan-depleted media, and added increasing 241 
concentrations of tryptophan or indole at 36 h PI to rescue the C. trachomatis 242 
D from tryptophan starvation (Figure 3A, B). Exogenous levels of tryptophan 243 
were able to effectively rescue the Chlamydia, with a maximum level of 244 
recovery of 2x104 IFU/ml, while there was no competition from the host cell over 245 
the tryptophan, as the cultures were treated with cycloheximide (Figure 3A).  246 
Indole rescue on the other hand, showed a maximum recovery level of 7.6x104 247 
IFU/ml with concentration dependent increase in the Chlamydia infectivity after 248 
tryptophan starvation (Figure 3B). When no rescue treatment was used, there 249 
were no inclusions detected at 72 h PI ("No rescue"), as well as at the time of 250 
reactivation of the cultures; 36 h PI (data not shown). 251 
Figure 3 goes here 252 
C. trachomatis rescue using indole-producing bacterial supernatants 253 
In order to investigate whether supernatant from indole producing bacteria 254 
could rescue Chlamydia, we chose two indole producing Prevotella spp. (P. 255 
intermedia and P. nigrescens) and one indole-negative strain, P. bivia. The 256 
bacteria were incubated in brain heart infusion (BHI) medium for 36 h. As the 257 
BHI growth medium contains tryptophan, we included the medium alone as a 258 
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control and tested it at a range of dilutions (1:1,000, 1:5,000, and 1:10,000). 259 
Only supernatant from the indole-positive bacteria (P. intermedia and P. 260 
nigrescens) were able to rescue the Chlamydia at the critical dilution of 261 
1:10,000 (Figure 4) (p value<0.0001 relative to BHI). By comparison, P. bivia, 262 
which is indole negative, was not able to rescue the Chlamydia at the same 263 
dilution (p value<0.0001 relative to P. bivia). When no rescue treatment was 264 
used, there were no inclusions detectable, at 72 h PI, as well as at the time of 265 
reactivation of the cultures; 36 h PI (data not shown). 266 
Figure 4 goes here 267 
C. trachomatis rescue using vaginal secretions from Chlamydia positive 268 
and Chlamydia negative women 269 
We utilised a combination of in vitro and ex vivo model to test the hypothesis 270 
that some of the vaginal indole-producing microbiota may counteract the 271 
immune system response mediated by IFN-γ, by providing a source of indole 272 
and allows the Chlamydia to survive under tryptophan-depleted conditions. 273 
Specifically, we tryptophan-starved the C. trachomatis D strain using 274 
tryptophan depleted media. We then wanted to determine if vaginal secretions 275 
from different women was able to rescue the infectivity of Chlamydia to differing 276 
degrees, perhaps related to indole levels in these secretions. We therefore 277 
evaluated the Chlamydia recovery of infectivity compared with the participants' 278 
chlamydial status (positive/ negative) and the amount of indole in the vaginal 279 
secretions. The indole concentrations from the participants' secretions 280 
(indicated in Figure 5), ranged from 2.18 to 7.35mM. Participant's vaginal 281 
secretions were added to the C. trachomatis infected culture after tryptophan 282 
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starvation for 36 h PI. We found higher recovery levels of the Chlamydia 283 
following rescue with secretions from participants 111 and 211 with relatively 284 
high indole concentrations (4.76 mM and 6.06 mM respectively) (Figure 5). 285 
However, using secretions from participant 112 and 213 (who had relatively low 286 
indole concentrations in their secretions of 2.18 mM and 3.74 mM respectively) 287 
resulted in lower recovery of the C. trachomatis after tryptophan starvation in 288 
vitro (2 x 103 and 1.6 x 103 IFU/ml respectively). Across all five participants 289 
there was no linear correlation of indole and chlamydial recovery, however, four 290 
of the five participants were consistent with a trend of higher indole resulting in 291 
higher chlamydial infection.  Spiking the participants' secretions with 0.5 µM 292 
indole (at dilution of '1:10,000+'), eliminated some of the differences in the 293 
Chlamydia recovery that were found between the participants (dilution of 1:100) 294 
(Supplementary Figure 3). No significant differences were observed between 295 
participant's secretions treatments in dilutions 1:1,000 and 1:10,000 296 
(Supplementary Figure 3). When no rescue treatment was used, there were no 297 
inclusions detected, at 72 h PI, as well as at the time of reactivation of the 298 
cultures; 36 h PI (data not shown). 299 
Figure 5 goes here 300 
trpBA gene expression in tryptophan starved C. trachomatis D following 301 
different rescue conditions 302 
In an attempt to gain further support for the hypothesis, that the response of the 303 
tryptophan-starved C. trachomatis to the availability of tryptophan and indole 304 
(added as a rescue treatment 36 h PI) involves their tryptophan biosynthesis 305 
genes, we measured the mRNA expression levels of the trpBA gene in our 306 
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indole-producing bacterial supernatant model (Figure 6). Tryptophan starvation 307 
was shown to induce trpBA transcription levels in C. trachomatis culture ('No 308 
rescue 72 h PI'. Figure 6A). When exogenous tryptophan is provided via the 309 
DMEM medium, trpBA levels are switched off.  (as expected), and hence any 310 
evidence of trpBA expression indicates a tryptophan starvation state of the 311 
Chlamydia. When exogenous indole was provided (at 0.5 and 5 µM), the trpBA 312 
gene expression levels were again increased to some extent, presumably to 313 
convert the indole to more tryptophan. (Figure 6A). We then assessed the effect 314 
of adding bacterial supernatants (at various dilutions) to the chlamydial cultures 315 
and found that for P. bivia (indole negative) the chlamydial trpBA expression 316 
was high, confirming that they were tryptophan starved (Figure 6B). By 317 
comparison, the trpBA levels for the two indole positive bacteria (P. intermedia 318 
and P. nigrescens) were significantly lower (p value <0.05).  319 
Figure 6 goes here 320 
Discussion 321 
In this study, we investigated the role of indole in the recovery of urogenital C. 322 
trachomatis infections following tryptophan starvation in vitro. The current 323 
hypothesis argues that the availability of indole in the lower genital tract site of 324 
women infected with C. trachomatis, can influence the level and outcome of the 325 
infection. Using both the established IFN-γ model as well as a tryptophan-326 
depleted media model, we found that supernatants from the indole-positive 327 
bacteria, P. intermedia and P. nigrescens, but not indole-negative P. bivia, were 328 
able to recover C. trachomatis D infectivity when added to the cultures at 329 
dilution of 1:10,000. Although there is a range of bacterial products being 330 
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produced by indole-positive bacteria cultured in broth medium, we assume that 331 
indole is a critical compound, which directly have a positive effect on C. 332 
trachomatis recovery after tryptophan starvation in vitro. Treatment with 333 
supernatant of indole-negative P. bivia and the control (BHI) were not sufficient 334 
to rescue the Chlamydia using the same dilution of 1:10,000. Because the 335 
amount of bacteria in a growth medium and the concentration of cytotoxic 336 
compounds are much higher than the levels found in vivo, we diluted the 337 
bacterial supernatants (1:1,000, 1:5,000 and 1:10,000). We also included a 338 
control of the bacterial growth broth (BHI). We have tested the BHI medium for 339 
tryptophan concentration, using commercial tryptophan ELISA kit (ImmuSmol, 340 
France), in order to validate our conclusion from this experiment. BHI medium 341 
contains 35 µg/ml (0.17 µM) tryptophan and therefore, it might have affected 342 
the recovery levels of the tryptophan-starved Chlamydia culture. However, 343 
when diluting the BHI medium to 1:10,000, the tryptophan in the medium itself 344 
was reduced to 3.5 ng/ml, which was previously shown to be insufficient for the 345 
recovery of Chlamydia after tryptophan starvation [22,29]. Accordingly, BHI 346 
rescue treatment at a dilution of 1:1,000 had significantly lower recovery 347 
compared to P. intermedia at the same dilution (p value <0.005, suggesting that 348 
indole in the P. intermedia supernatant had a beneficial effect, resulting in 349 
higher Chlamydia recovery in compare to the BHI control (Supplementary 350 
Figure 2). 351 
Indole concentrations measured from the growth medium of P. intermedia and 352 
P. nigrescens were 300 µM and 250µM respectively. When diluting the 353 
supernatant 1:1,000, the indole concentration was decreased to 0.25-0.3 µM 354 
(Supplementary Figure 2). However, treatment with the indole-positive bacterial 355 
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supernatant at this dilution, resulted in significantly higher recovery of the 356 
Chlamydia (P. intermedia: 6.8 x 104 IFU/ml, P. nigrescens: 3.1 x 104 IFU/ml) 357 
(p<0.0001), in comparison to the control in which exogenous indole was directly 358 
added to a level of 0.5 µM (3.8 x 103 IFU/ml; Supplementary Figure 2). This 359 
suggests again that the recovery effect from the bacterial supernatant may be 360 
further increased as a result of the tryptophan content in the media, in addition 361 
to the indole produced by the indole-positive Prevotella.   362 
Measurements of the chlamydial trpBA were conducted in order to confirm our 363 
recovery data during the different bacterial supernatant rescue treatments. 364 
Significantly higher expression levels in P. bivia supernatant rescue, suggested 365 
that there was no recovery of the tryptophan-starved Chlamydia via exogenous 366 
indole/tryptophan addition. This confirms our assumption that a non-indole 367 
producing bacterium such as P. bivia, is not able to rescue the Chlamydia after 368 
tryptophan starvation. trpBA measurements in indole positive bacterial 369 
supernatants (Figure 6B) indicated lower expression levels in comparison to 370 
the tryptophan-starved Chlamydia ('No rescue 72 h PI'; Figure 6A), probably 371 
caused by the presence of indole in the media.   372 
In order to investigate whether differences in the indole content in vaginal 373 
secretions of women who are negative for, or infected with C. trachomatis, have 374 
different effects on tryptophan starved C. trachomatis recovery in vitro, we used 375 
the same tryptophan free media model. We found that low indole content in 376 
secretions from participants 112 and 213 corresponded with lower Chlamydia 377 
recovery indicated by IFU/ml. Higher indole concentration in secretions from 378 
participants 111 and 211 corresponded with a higher Chlamydia recovery effect 379 
at a dilution of 1:100. This might suggest that high indole concentrations in the 380 
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women's secretions contribute to higher recovery of the tryptophan-starved C. 381 
trachomatis culture in vitro. C. trachomatis-positive participants 211 and 306 382 
had considerably higher levels of indole in their secretions (7.35 mM and 6.6 383 
mM respectively). This could indicate a link between Chlamydia infection status 384 
(positive/negative) and the indole concentrations measured from their genital 385 
secretions.    386 
Individuals vary in their susceptibility to C. trachomatis infections, both new 387 
infections, as well as repeat infections [44–46]. While there are many factors 388 
that might contribute to this variation, such as individual sexual patterns [46], 389 
innate and adaptive immune response [47], the expression and release of the 390 
key cytokine IFN-γ [23], one additional factor that might influence this infection 391 
variation is the composition of the vaginal microbiome [33,48,49]. In most 392 
healthy women, lactobacilli are numerically dominant in the lower genital tract, 393 
providing protection against a range of pathogenic bacteria and resulting in a 394 
lower pH in this environment [50–53]. The replacement of lactobacilli by 395 
fastidious anaerobes, such as Prevotella spp., can result in higher pH, dysbiosis 396 
and bacterial vaginosis (BV) [48,54]. It is well known that women with BV have 397 
a higher risk of acquiring sexually transmitted infections such C. trachomatis 398 
[33,55–57]. Some of these BV associated Prevotella are also indole positive, 399 
although this balance may well be quite different between different individuals. 400 
Indole production in the lower genital tract can also be associated with higher 401 
pH and lower numbers of lactobacilli. Our data clearly show that supernatant 402 
from indole positive but not indole negative Prevotella strains can rescue C. 403 
trachomatis from tryptophan starvation, in this in vitro model. It is possible that 404 
other indole-producing bacteria (e.g. Porphyromonas gingivalis, 405 
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Propionibacterium acnes, Fusobacterium nucleatum, Escherichia coli or 406 
Enterococcus faecalis) which have been reported to colonize the genital tract 407 
in dysbiosis, could have a similar effect. If this hypothesis is confirmed, it opens 408 
up additional means of therapy for women who get frequent C. trachomatis 409 
infections. Such therapies might include probiotics and other interventions to 410 
the vaginal microbiota in order to restore a healthy, acidic, lactobacilli dominant 411 
environment. 412 
Conclusions 413 
Our results give further support to the hypothesis that some members of the 414 
genital microbiota, such as Prevotella, are able to produce indole and this might 415 
influence the natural course of C. trachomatis infection in women, by providing 416 
a substrate for the Chlamydia to produce tryptophan, which enables them to 417 
escape the host’s IFN-γ-mediated immune response. We demonstrated that 418 
supernatants from indole-producing bacteria were efficient in assisting the 419 
recovery of the Chlamydia after tryptophan starvation in vitro, in comparison to 420 
non-indole producers. By directly testing vaginal secretions from a range of 421 
women, we found that higher levels of indole in the vaginal secretions from 422 
some women contributed to the recovery of tryptophan-starved C. trachomatis 423 
culture in vitro. Thus for the first time we have provided ex vivo evidence that 424 
indole production in the vagina might have a key role in the outcome of genital 425 
Chlamydia infections and could lead to the development of novel therapies. 426 
 427 
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Fig. 1: Recovery of IFN-γ treated C. trachomatis (ocular; C and genital; D strains), 647 
with tryptophan (DMEM) and indole (10µM). Monolayers of HEp-2 cells were seeded 648 
48 h before infection in the presence of different IFN-γ concentrations (0, 150, 500 649 
U/ml). IFN-γ treatment was replenished every 24 h throughout the whole experiment. 650 
Cells were infected with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 651 
h. The Chlamydia infected cultures were allowed to recover for 24 h in the presence of 652 
tryptophan (DMEM) or indole (10µM). Infected cells and culture supernatants were 653 
sonicated and used to infect a new HEp-2 cell monolayer for enumeration of 654 
recoverable IFUs. Data are presented as the mean ± SD IFU/ml (n=9) determinations. 655 
 656 
Fig. 2: Effect of different indole concentrations on the recovery of C. trachomatis 657 
D following IFN-γ treatment. Monolayers of HEp-2 cells were seeded 48 h before 658 
infection in the presence of different IFN-γ concentrations (0, 150, 500 U/ml). IFN-γ 659 
treatment was replenished every 24h throughout the whole experiment. Cells were 660 
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infected with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 h. The 661 
Chlamydia infected cultures were allowed to recover for 24 h with different indole 662 
concentrations (0.1, 0.25, 0.5, 1µM). Infected cells and culture supernatants were 663 
sonicated and used to infect a new HEp-2 cell monolayer for enumeration of 664 
recoverable IFUs. Data are presented as the mean ± SD IFU/ml (n=9) determinations. 665 
 666 
Fig. 3: Recovery of tryptophan-starved C. trachomatis strain D after rescue with 667 
exogenous tryptophan (122-980 µM) or indole (0.1-10 µM). Monolayers of HEp-2 668 
cells were seeded in the presence of tryptophan depleted media 24 h before infection. 669 
Cells were infected with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 670 
h. The Chlamydia infected cultures were allowed to recover for 36 h with increasing 671 
concentrations of tryptophan (A) or indole (B). Infected cells and culture supernatants 672 
were sonicated and used to infect a new HEp-2 cell monolayer for enumeration of 673 
recoverable IFUs. Data are presented as the mean ± SD IFU/ml (n=9) determinations. 674 
 675 
Fig. 4: Recovery of tryptophan-starved C. trachomatis strain D after rescue with 676 
supernatant from indole positive/ indole negative bacteria. Monolayers of HEp-2 677 
cells were seeded in the presence of tryptophan depleted media 24 h before infection. 678 
Cells were infected with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 679 
h. The Chlamydia infected cultures were allowed to recover for 36 h in the presence of 680 
(A) supernatant from indole producing P. intermedia and P. nigrescens, and a non-681 
indole producer P. bivia. Data are presented in dilution of 1:10,000. P. bivia is 682 
significantly different (p<0.0001).  Indole concentrations measured from the growth 683 
medium of P. intermedia and P. nigrescens were 300 µM and 250µM respectively. (B) 684 
A control of the bacterial growth broth (BHI) was added as well. All treatments were 685 
added in different dilutions of 1:1,000, 1:5,000 and 1:10,000 (Supplementary Figure 2). 686 
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Infected cells and culture supernatants were sonicated and used to infect a new HEp-687 
2 cell monolayer for enumeration of recoverable IFUs. Data are presented as the mean 688 
± SD IFU/ml (n=9) determinations. Statistical significance determined via multiple t 689 
testing using the Holm-Sidak method, with alpha = 0.05. Each row was analyzed 690 
individually, without assuming a consistent SD. 691 
 692 
Fig. 5: Recovery of tryptophan-starved C. trachomatis strain D after rescue with 693 
secretions from five (Chlamydia positive/negative) participants that have 694 
different concentrations of indole in their vaginal secretions. Monolayers of HEp-695 
2 cells were seeded in the presence of tryptophan depleted media 24 h before infection. 696 
Cells were infected with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 697 
h. The Chlamydia infected cultures were allowed to recover for 36 h in the presence of 698 
secretions from two C. trachomatis negative participants (111 and 112) and three C. 699 
trachomatis positive participants (213, 211 and 306). Chlamydia test (CT+/CT-), pH 700 
and BV conditions are indicated in boxes above each participant. Secretions were 701 
added to the cultures at dilution of 1:100. Axis X represent the indole concentrations 702 
measured from the participants' secretions, axis Y represent the recovery effect of the 703 
Chlamydia in IFU/ml. Infected cells and culture supernatants were sonicated and used 704 
to infect a new HEp-2 cell monolayer for enumeration of recoverable IFUs. Data are 705 
presented as the mean ± SD IFU/ml (n=9) determinations. 706 
 707 
Fig. 6: RT-qPCR quantitation of trpBA gene mRNA, isolated from HEp-2 cells, 708 
infected with C. trachomatis strain D during tryptophan starvation conditions 709 
and rescue. C. trachomatis infected cultures and conditions were as described in the 710 
legend of Figure 4 and 5. (A) Total RNA was isolated from infected cultures grown in 711 
tryptophan depleted media at 72 h PI ('No rescue'), and after indole rescue in different 712 
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concentrations (0.5, 5 µM), as well as complete DMEM conditions harvested at 36 and 713 
72 h PI ('DMEM'). No rescue treatment is significantly different p<0.0001. (B) trpBA 714 
transcript levels were measured from rescue treatments of infected cultures using 715 
indole positive bacterial supernatant (P. intermedia, P. nigrescens) and indole negative 716 
(P. bivia), applied in dilution of 1:10,000. P. bivia is significantly different p<0.005.  717 
